Chardan analyst Keay Nakae raised the firm’s price target on Coya Therapeutics to $14 from $11 and keeps a Buy rating on the shares following the Q4 report. Management has refined the company’s development pipeline, which will now focus of development of COYA 302, “pipeline in a product” targeting multiple neurodegenerative diseases, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COYA: